This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

Is sertraline treatment or depression remission in depressed Alzheimer patients associated with improved caregiver well being? Depression in Alzheimer’s Disease Study 2


Flynn Longmire, Crystal V., Drye, Lea T., Frangakis, Constantine E., Martin, Barbara K., Meinert, Curtis L., Mintzer, Jacobo E., Munro, Cynthia A., Porsteinsson, Anton P., Rabins, Peter V., Rosenberg, Paul B., Schneider, Lon S., Weintraub, Daniel, Lyketsos, Constantine G.


The American Journal Of Geriatric Psychiatry: Official Journal Of The American Association For Geriatric Psychiatry, Volume: 22, No.: 1, Pages.: 14-24

Year of Publication



Objective: We wanted to assess if sertraline treatment (versus placebo) or remission of depression at 12 weeks (versus nonremission) in Alzheimer patients is associated with improved caregiver well being.; Methods: We conducted a randomized, double-blind, placebo-controlled clinical trial of the efficacy and safety of sertraline for the treatment of depression in individuals with Alzheimer disease in five clinical research sites across the United States. Participants were caregivers of patients enrolled in the Depression in Alzheimer’s Disease Study 2 (N = 131). All caregivers received standardized psychosocial support throughout the study. Caregiver outcome measures included depression (Beck Depression Inventory), distress (Neuropsychiatric Inventory), burden (Zarit Burden Interview), and quality of life (Medical Outcomes Study Short Form Health Survey).; Results: Fifty-nine percent of caregivers were spouses, 63.4% were women, and 64.1% were white. Caregivers of patients in both treatment groups had significant reductions in distress scores over the 24-week study period, but there was not a greater benefit for caregivers of patients taking sertraline. However, caregivers of patients whose depression was in remission at week 12 had greater declines in distress scores over the 24 weeks than caregivers of patients whose depression did not remit by week 12.; Conclusion: Patient treatment with sertraline was not associated with significantly greater reductions in caregiver distress than placebo treatment. Distress but not level of depression or burden lessened for all caregivers regardless of remission status and even more so for those who cared for patients whose depression remitted. Results imply an interrelationship between caregiver distress and patient psychiatric outcomes.; Copyright © 2014 American Association for Geriatric Psychiatry. Published by Elsevier Inc. All rights reserved.

Bibtex Citation

@article{Flynn_Longmire_2014, doi = {10.1016/j.jagp.2013.02.014}, url = {}, year = 2014, month = {jan}, publisher = {Elsevier {BV}}, volume = {22}, number = {1}, pages = {14--24}, author = {Crystal V. Flynn Longmire and Lea T. Drye and Constantine E. Frangakis and Barbara K. Martin and Curtis L. Meinert and Jacobo E. Mintzer and Cynthia A. Munro and Anton P. Porsteinsson and Peter V. Rabins and Paul B. Rosenberg and Lon S. Schneider and Daniel Weintraub and Constantine G. Lyketsos}, title = {Is Sertraline Treatment or Depression Remission in Depressed Alzheimer Patients Associated with Improved Caregiver Well Being? Depression in Alzheimer{textquotesingle}s Disease Study 2}, journal = {The American Journal of Geriatric Psychiatry} }


adverse effects, aged, alzheimer disease, antidepressants, caregivers, complications, cost of illness, dementia, depression, diads2, double-blind method, drug therapy, female, for, humans, impact, male, middle aged, nursing, of, ppl, psychiatric status rating scales, psychology, quality of life, remission spontaneous, sertraline, stress, psychological, therapeutic use, with

Countries of Study


Types of Dementia

Alzheimer’s Disease

Types of Study

Randomised Controlled Trial

Type of Outcomes

Carer Burden (instruments measuring burden), Carers’ Mental Health, Quality of Life of Carer

Type of Interventions

Intervention for Carers, Pharmaceutical Interventions

Pharmaceutical Interventions

Antipsychotics and antidepressants

Carer Focussed Interventions